Author: Griggs, David W ; Teixeira, José E ; Oboh, Edmund ; Peek, Hannah ; Oliva, Jonathan ; Sverdrup, Francis M ; Philo, Emily ; Huston, Christopher D ; Schubert, Tanner J ; Stebbins, Erin E ; Meyers, Marvin J ; Miller, Peter

Our previous work identified compound 1 (SLU-2633) as a potent lead compound toward the identification of a novel treatment for cryptosporidiosis, caused by the parasite Cryptosporidium (EC₅₀ = 0.17 μM). While this compound is potent and orally efficacious, the mechanism of action and biological target(s) of this series are currently unknown. In this study, we synthesized 70 compounds to develop phenotypic structure-activity relationships around the aryl "tail" group. In this process, we found that 2-substituted compounds are inactive, confirmed that electron withdrawing groups are preferred over electron donating groups, and that fluorine plays a remarkable role in the potency of these compounds. The most potent compound resulting from this work is SLU-10482 (52, EC₅₀ = 0.07 μΜ), which was found to be orally efficacious with an ED₉₀ < 5 mg/kg BID in a Cryptosporidium-infection mouse model, superior to SLU-2633.

Journal of Medicinal Chemistry

Structure-Activity Relationship Studies of the Aryl Acetamide Triazolopyridazines against Cryptosporidium Reveals Remarkable Role of Fluorine

Author: Teixeira, Jose E. ; Oboh, Edmund ; Sverdrup, Francis M. ; Peek, Hannah ; Miller, Peter ; Philo, Emily ; Meyers, Marvin J. ; Huston, Christopher D. ; Schubert, Tanner J. ; Oliva, Jonathan ; Griggs, David W. ; Stebbins, Erin E.

Our previous work identified compound 1 (SLU-2633) as a potent lead compound toward the identification of a novel treatment for cryptosporidiosis, caused by the parasite Cryptosporidium (EC50 = 0.17μM).While this compound is potent and orally efficacious, the mechanism of action and biol. target(s) of this series are currently unknown.In this study, we synthesized 70 compounds to develop phenotypic structure-activity relationships around the aryl "tail" group.In this process, we found that 2-substituted compounds are inactive, confirmed that electron withdrawing groups are preferred over electron donating groups, and that fluorine plays a remarkable role in the potency of these compoundsThe most potent compound resulting from this work is SLU-10482 (52, EC50 = 0.07μΜ), which was found to be orally efficacious with an ED90 < 5 mg/kg BID in a Cryptosporidium-infection mouse model, superior to SLU-2633.

100 Deals associated with SLU-10482

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cryptosporidiosis	Discovery	United States	Saint Louis University (Madrid)	02 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SLU-10482

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation